BioNJ President and CEO Debbie Hart in a recent column published on NJ Spotlight describes the rising interest in using value assessments in health plans’ coverage decisions as a “troubling” development.
Hart takes aim at the Institute for Clinical and Economic Review’s (ICER) assessment as the organization’s reports continue to gain credibility.
“ICER ignores real-life patient experiences in its reviews, instead basing its determinations of a drug’s value on financial considerations alone,” she writes. “Their method applies an arbitrary monetary value (in the range of $100,000) to one year of ‘perfect health.'”
To read Hart’s full write up, click here.